SEBI refuses to take note of price manipulation in Transgene Biotek – Part I  

March 11, 2014

SEBI, which is preaching to world about corporate governance, has ignored investor complaints about GDR scam and blatant manipulation of Transgene Biotek shares. This is first part of a two-part series

Moneylife Digital Team

Minority shareholders of Transgene Biotek Ltd have alleged misuse of global depository receipts (GDRs)—a financial instrument used to raise capital overseas, and several “well-timed” announcements by the company.

To read more on this click here